FDA Mulling Over Next Move Following Mifepristone Ruling

The US Food and Drug Administration’s authority to approve medications is on the line, following a Texas judge shooting down the decades-old approval of the abortion medication mifepristone. With this development, the agency is looking for ways to preserve its powers while keeping mifepristone on the market. The strategy will depend on an appeal at the Fifth Circuit tomorrow.

According to Zachary Brennan, “If the Department of Justice’s appeal at the Fifth Circuit is denied tomorrow, the government will likely seek emergency relief from the Supreme Court, especially given the other order from a Washington state court, according to the law firm Ropes & Gray. While that process is ongoing, mifepristone would remain on the market.”

To read more, click here.

(Source: Zachary Brennnan, April 12^th, 2023)